Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Operations of Simcere’s Latest Acquisition Remain Shut Down

publication date: Apr 5, 2010
Simcere Pharmaceutical Group (先声药业)reported that a recent acquisition, Jiangsu Yanshen Biological Technology, committed fraud with respect to its human-use rabies vaccine before Simcere bought its controlling interest in October 2009. As soon as Simcere found out about the problem, it urged Jiangsu Yanshen’s board to cease operations and review the company’s quality control. It has complied with the official investigation into the situation. More details...

Stock Symbol: (NYSE: SCR)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital